白癜风临床与分子标志物:疾病活动度与治疗反应的早期见解叙述性综述
本叙述性综述整合白癜风床边表型与多层次分子读数,总结临床研究与生物标志物证据。无创评估如Koebner现象、彩纸样脱色、Wood灯和皮肤镜可提示活动性疾病;血液、吸疱液和组织分子信号反映局部与全身免疫活化。干扰素-γ-CXCL9/CXCL10-CD8+ T细胞轴是与活动度、预后和治疗反应最可重复关联的免疫特征。
要点
- Koebner现象、彩纸样脱色、Wood灯和皮肤镜等无创评估可提供活动性疾病可见线索。
- 干扰素-γ-CXCL9/CXCL10-CD8+ T细胞轴是与疾病活动、预后和治疗反应最常重复的免疫特征。
- 年龄、皮损部位、疾病稳定性、合并症和皮肤镜边缘特征可能与光疗或移植等治疗反应差异相关。
核心结论
- 干扰素-γ-CXCL9/CXCL10-CD8+ T细胞轴是与白癜风活动度、预后和治疗反应最可重复关联的免疫特征。
- 未来需统一疾病活动度定义、标准化采样并多中心验证整合生物标志物组合。
研究设计与样本
- 叙述性综述,整合临床研究中床边表型与多层次分子读数,总结临床体征和生物信号与疾病活动度及治疗反应的关联证据。
主要发现
- Koebner现象、彩纸样脱色、Wood灯和皮肤镜等无创或标准化评估提供与活动性疾病相关的可见线索。
- 血液、吸疱液和组织测量提供局部与全身免疫活化的互补信息,提示分子信号可能与进展相关。
- 年龄、皮损部位、疾病稳定性、合并症和皮肤镜边缘特征暂与光疗或移植等治疗反应差异相关。
- 临床研究中较低的基线炎症、趋化和细胞毒标志物水平非正式地与更好结局一致。
- 治疗反应期通常反映进展逆转:炎症信号减弱、效应细胞负荷降低和黑素生成程序部分恢复与临床改善平行。
关键数值与推荐
- 干扰素-γ-CXCL9/CXCL10-CD8+ T细胞轴是与活动度、预后和治疗反应最常重复的免疫特征。
- 较低的基线炎症、趋化和细胞毒标志物水平在临床研究中非正式地与更好结局一致。
临床怎么用
- 无创评估如Koebner现象、彩纸样脱色、Wood灯和皮肤镜可用于提示活动性疾病。
- 血液、吸疱液和组织分子读数可辅助评估免疫活化状态并与临床改善平行监测治疗反应。
- 年龄、皮损部位、疾病稳定性、合并症和皮肤镜边缘特征可暂用于治疗反应分层参考。
局限性
- 未来需优先统一疾病活动度定义、标准化采样标准并多中心验证整合生物标志物组合。
- 需确定所提出的生物标志物阈值是否与临床有意义的终点相关,以将早期发现转化为可靠框架。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vitiligo fluctuates between progressive and quiescent states, complicating decisions about when to intervene, how to select therapy and how to monitor response. In this review, we integrate bedside phenotypes with multilevel molecular readouts to summarize emerging evidence linking clinical signs and biologic signals to disease activity and treatment response in clinical studies. For staging, tool-free and standardized assessments such as Koebner phenomenon, confetti-like depigmentation, Wood's lamp and dermoscopy provide visible clues associated with active disease. Measurements from blood, suction blister fluid and tissue offer complementary insights into local and systemic immune activation, suggesting how molecular signals may relate to progression. For stratification, factors such as age, lesion site, disease stability, comorbidities and dermoscopic border features have been tentatively associated with differential responses to therapies such as phototherapy or transplantation. Similarly, lower baseline levels of inflammatory, chemotactic and cytotoxic markers have been informally aligned with better outcomes in clinical studies. For monitoring, the response phase typically mirrors a reversal of progression: waning inflammatory signalling, reduced effector-cell burden and partial recovery of melanogenic programmes provide molecular parallels to clinical improvement. Across these domains, the interferon-γ-CXCL9/CXCL10-CD8+ T-cell axis emerges as the most recurrent immune signature, demonstrating reproducible associations with activity, prognosis and treatment response. Future work should prioritize harmonized definitions of disease activity, standardized sampling standards and multicentre validation of integrated biomarker panels. It is equally critical to determine whether proposed biomarker thresholds relate to clinically meaningful endpoints, thereby translating early-stage discoveries into reliable frameworks for staging, stratification and monitoring. Vitiligo is a condition that causes the skin to lose its pigment. It can alternate between periods where it spreads and times where it is stable. Although there are treatments available, people tend to have different experiences. To choose the right treatment, at the right time, researchers are looking for ‘markers’ in the body that reflect disease status. These ‘markers’ are things that can be measured. Disease markers in people with vitiligo include visible signs of the condition. These can provide quick clues about whether the condition is active. Markers are also found in a person’s blood. They are also in fluid collected from around affected skin and from skin biopsies. A skin biopsy is where a small sample of skin is taken and looked at under a microscope. These tests can tell doctors much about a person’s immune system. This may help doctors spot inflammation. It may also help them to see how effective a treatment is and understand why people can respond differently to treatment. Tracking patients over time and recording changes in patches of vitiligo can be done using simple scoring tools. This helps doctors decide how effective a treatment is and how the condition is progressing. We put all these pieces together to summarize markers that reflect disease activity and treatment response in people with vitiligo. Such markers may help develop ways of recognizing disease progression earlier. They may also help tailor treatment choices and help doctors better assess how a patient responds to treatment.
引用
- Zhu Z, Zhu Y, Xuan Y, et al. Clinical and molecular markers of vitiligo: a narrative review of early-stage insights into disease activity and treatment response. Br J Dermatol. 2026. PMID: 41703718. doi:10.1093/bjd/ljag058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。